Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
AUPH Stock Chart & Stats
$14.37
$0.10(1.19%)
At close: 4:00 PM EST
$14.37
$0.10(1.19%)
Day’s Range― - ―
52-Week Range$6.83 - $16.54
Previous CloseN/A
Volume460.34K
Average Volume (3M)1.03M
Market Cap
$1.94B
Enterprise Value$1.94B
Total Cash (Recent Filing)$398.00M
Total Debt (Recent Filing)$74.81M
Price to Earnings (P/E)7.5
Beta0.44
Next Earnings
Apr 30, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.53
Shares Outstanding132,970,980
10 Day Avg. Volume1,103,507
30 Day Avg. Volume1,030,941
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.69
Price to Sales (P/S)7.57
P/FCF Ratio15.83
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue6.84
Enterprise Value/Gross Profit7.73
Enterprise Value/Ebitda13.60
Forecast
1Y Price Target
$16.00Price Target Upside11.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.94
Revenue Forecast (FY)$326.80M
Bulls Say, Bears Say
Bulls Say
Clinical Guidelines Driving AdoptionUpdated lupus nephritis and rheumatology guidelines that promote proactive proteinuria screening are expanding diagnosis and creating more treatment starts for Lupkynis.
Commercial Momentum And Operational ExecutionLupkynis sales have exceeded expectations and management projects continued growth even with a reduced sales force, indicating durable commercial demand and efficient resource allocation.
Pipeline Clinical ProgressEarly aritinercept clinical signals, including strong immunoglobulin reductions and high binding affinity, support a potential once-monthly dosing profile that could meaningfully expand the autoimmune pipeline.
Bears Say
Competitive RiskApproval of a rival lupus nephritis therapy increases competitive pressure and could temper Lupkynis market share gains despite its faster onset of action.
Cost And Legal PressureInitiation of clinical trials together with ongoing patent litigation is likely to raise operating expenses and pressure near-term profitability.
Intellectual Property UncertaintyMultiple generic challenges to the key dosing patent create uncertainty around long-term exclusivity and could weigh on future sales.
Aurinia Pharmaceuticals News
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $6.83 and its highest was $16.54 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $1.94B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Apr 30, 2026 which is in 34 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Feb 26, 2026. The company reported $1.53 earnings per share for the quarter, beating the consensus estimate of $0.217 by $1.313.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is 0.2.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 132,970,980 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of $1.53 in its last earnings report, beating expectations of $0.217. Following the earnings report the stock price went down -3.188%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (11.34% Upside)
$16.00 (11.34% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.74%
12-Months-Change
Fundamentals
Return on Equity
70.37%
Trailing 12-Months
Asset Growth
39.94%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
AUPH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights robust commercial momentum for LUPKYNIS with double-digit top-line growth, materially improved cash generation, a strong balance sheet and share repurchases. Management provided constructive 2026 guidance and disclosed promising early clinical results for aritinercept. Offsetting these positives are a significant one-time tax benefit that materially boosted reported net income, termination of a pediatric study (creating regulatory follow-up risk), emerging competition (Gazyva), limited near-term transparency on quarterly performance, and early-stage development uncertainties (ADAs). Overall, the positives—sustained product revenue growth, strong cash flow, and advancing pipeline—outweigh the headwinds, though some risks remain.View all AUPH earnings summariesAUPH Revenue Breakdown
90.00% U.S.
10.00% Japan
AUPH Stock 12 Month Forecast
Average Price Target
$16.00
▲(11.34% Upside)
Technical Analysis
Ownership Overview
11.26% Insiders
4.15% Mutual Funds
17.84% Other Institutional Investors
59.81% Public Companies and
Individual Investors